Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IHJ-301 iPSC-derived cardiovascular cell sheet therapy for dilated cardiomyopathy
jRCT2033240447Recruiting
- Sponsor
- iHeart Japan
- Start
- Oct 2024
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of IHJ-301 in dilated cardiomyopathy (DCM), sponsored by iHeart Japan. Primary endpoint: Safety of IHJ-301 cardiovascular cell sheet therapy under immunosuppression. Started Oct 2024; status: recruiting.
02
Drugs
IHJ-301
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on jRCT2033240447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240447.